Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT05737602
Status
Enrolling By Invitation

Conditions

  • Genetic Disorder
  • Von Hippel-Lindau Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 3RP-VHL — BEHAVIORAL
    An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.

Study Details

The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.

Key Dates

Start date
Jul 30, 2024
Status verified
May 2025
Primary completion
May 1, 2026
Completion
Jul 1, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: 3RP-VHL
    * An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks. * Complete pre- and post-intervention surveys.

Primary Outcome Measure

3RP-VHL Feasibility: Percent of Identified Eligibles Who Enroll [ Time Frame: Post-treatment completion (treatment is approximately 2 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital Cancer CenterBostonMassachusetts02215-

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital Cancer Center· Boston, MA

Related Studies